Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. - Wikidata - wikimedia - TriplyDB

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

http://www.wikidata.org/entity/Q37457302

about

Disruption of IkappaB kinase (IKK)-mediated RelA serine 536 phosphorylation sensitizes human multiple myeloma cells to histone deacetylase (HDAC) inhibitors.Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy The DAC system and associations with multiple myeloma.Protein kinase CK2 inhibition down modulates the NF-κB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells.Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma Marine-derived angiogenesis inhibitors for cancer therapy.Antibody-maytansinoid conjugates for the treatment of myeloma.Development of target-specific treatments in multiple myeloma.Protein kinase networks regulating glucocorticoid-induced apoptosis of hematopoietic cancer cells: fundamental aspects and practical considerations.Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors.From cell biology to therapy: ENMD-2076 in the treatment of multiple myeloma.Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I.Novel anticancer agents for multiple myeloma: a review of the evidence for their therapeutic and economic value.New proteasome inhibitors in myeloma.Hes1 expression and CYLD repression are essential events downstream of Notch1 in T-cell leukemia.The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines.In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents.Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.Proteostasis: a new therapeutic paradigm for pulmonary disease.Erucylphosphohomocholine, the first intravenously applicable alkylphosphocholine, is cytotoxic to acute myelogenous leukemia cells through JNK- and PP2A-dependent mechanisms.In vitro effects of perifosine, bortezomib and lenalidomide against hematopoietic progenitor cells from healthy donors.The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells.

P2860

Q30424831-DD8DBCD2-1015-41AA-9787-7F216555228E Q34168461-5C04921A-9D63-42FB-8F26-6B5CAECEF5ED Q34212516-04109892-805D-460B-A96B-0C2810CD0DE8 Q34344053-EFD4D2FF-94DC-4297-9AE3-604151A576B8 Q34414447-DA1A6C09-AB48-491B-BA94-F3A0DBF81B80 Q35005510-D1F7885F-3691-48DE-AD38-E2535FFBAC64 Q35915726-C81DE001-3917-426F-8683-B4098C1E362D Q36994177-891BA08C-EE95-4C4C-9954-78A24B1FC8AB Q37672881-E59532EB-1094-4035-948F-2E4975985B95 Q37771370-7053DDC0-5835-49E0-B20A-F86C82A8E301 Q37789771-2EECA4FC-2475-48A9-B8DD-DB5AD6AF3FFC Q37813152-936B5E4D-AA01-4F90-99BD-C9D1CD26CA25 Q37880074-8EEDC163-8952-45CB-95CF-57B8A306CE01 Q37882459-F87848F7-3D7A-4D6D-9F12-46FAECFA3589 Q38020248-C1BA89E6-B069-4AFC-A054-86A11A51D7AC Q38052079-A86EA0EB-3C09-482D-B995-41073F5BC9E3 Q38607613-196C8791-5691-4E6F-81C3-D410264F67ED Q38940707-5D47351A-6DDC-4258-8BD9-C969BFF94754 Q38968027-FE5ED124-3703-4D26-B6C8-5D56001B293B Q39009323-1BC24989-9D89-4341-AC7A-2F96C84F0251 Q39202496-65B1204B-B8C4-4E8F-AFE2-7F6FB65F1DC3 Q39631346-4464EF9A-7CB0-42FD-B374-8ED8992B8499 Q42790541-6AFE9DBE-BF08-4868-B6D5-735233F8457D Q43143677-70ABF976-DBCB-47EB-A860-4B60B26FA9EA Q50436837-B320E45A-0484-42A4-947F-E8A8FD7F210F Q54539131-B77B1F09-2F45-4CEE-B83C-EC5AE50F83F8

P2860

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

http://www.wikidata.org/entity/Q37457302

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

@en

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

@nl

type

label

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

@en

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

@nl

prefLabel

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

@en

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

@nl

P1433

Q37457302-2EB939E2-5C04-4CBF-AE98-601EFF6CE2B5

P1476

Q37457302-37F8FBDA-A50E-4307-8171-5DD8568EF678

P2093

Q37457302-13C87082-5E0B-4E96-8745-18F2874D5DFE

Q37457302-41A915E0-7D5B-4919-B115-59F1086A2D96

Q37457302-64543CA4-542D-4395-8146-49DDA82E5C7D

Q37457302-6B5BD2E2-45E0-47AA-B9C0-A96EE93D8794

Q37457302-A2CDB0AA-0F54-4262-9011-8C747E1F5DD3

Q37457302-A380B917-E1C0-47FA-BD11-CF8B1B052F6E

Q37457302-C59C7A31-7D19-450B-A438-20EB096634E7

P2860

Q37457302-03F75448-82A1-43CD-B1BE-EFD81DFE1C23

Q37457302-063A7F1D-4546-46F6-9149-4F72D36382F4

Q37457302-063D6AD6-E3AE-4CAE-83D1-EF48771396F4

Q37457302-0B53B611-8873-4B2A-B27D-1AF90ADBE536

Q37457302-0D84F896-E2C1-455D-8E73-D3A7EF0D3228

Q37457302-11FE9564-6EB4-424E-B3BC-A7941490EB4E

Q37457302-1DBFD9E2-DD54-4D7D-8B07-01BBCC4A84B0

Q37457302-1E431941-07E3-4795-9CD6-DB815DB6C7F3

Q37457302-1ED3E580-4F19-4D4C-9E4D-7C7AC1E4DCF0

Q37457302-20866CF7-E72C-4064-84F3-5713992AF536

P304

Q37457302-46B586B4-8FE0-42DA-A0A6-CE6EAC1E2539

P31

Q37457302-98545E93-111F-49FB-87C6-D367F6BE6967

P356

Q37457302-8F26F9A2-2FBC-4980-BB91-BD5823E7125C

P433

Q37457302-C170AA1F-28F7-4D38-846E-7B4D15BFF11E

P478

Q37457302-12E553D9-3907-45BE-BE9C-BEB5B3262717

P50

Q37457302-BECC36C9-49BD-46F8-8169-693D9D692839

Q37457302-F05E8D89-AD91-4E0E-81AE-6ABF6ED6AFE1

P577

Q37457302-019CA6D2-A8B6-4574-881D-712C9E3F7066

P5875

Q37457302-039BFE69-98E9-4C1E-A228-3F6A662EBC31

P698

Q37457302-09AFD610-C3A2-41EB-A521-D4F5B93A3D29

P932

Q37457302-C8A5419C-6904-47B2-8A5A-0DE2D7646A5C

P356

J.SEMINHEMATOL.2009.02.003

P1433

Seminars in Hematology

P1476

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

@en

P2093

Constantine S Mitsiades

http://www.w3.org/2001/XMLSchema#string

Dharminder Chauhan

http://www.w3.org/2001/XMLSchema#string

Douglas W McMillin

http://www.w3.org/2001/XMLSchema#string

Jacob P Laubach

http://www.w3.org/2001/XMLSchema#string

Nikhil C Munshi

http://www.w3.org/2001/XMLSchema#string

Steffen Klippel

http://www.w3.org/2001/XMLSchema#string

Teru Hideshima

http://www.w3.org/2001/XMLSchema#string

P2860

Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays.

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

P304

166-175

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.SEMINHEMATOL.2009.02.003

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

46

http://www.w3.org/2001/XMLSchema#string

P50

Kenneth C Anderson

Paul G Richardson

P577

2009-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24354990

http://www.w3.org/2001/XMLSchema#string

P698

19389500

http://www.w3.org/2001/XMLSchema#string

P932

2746942

http://www.w3.org/2001/XMLSchema#string